ADIM
IONS icon

Alpha DNA Investment Management’s Ionis Pharmaceuticals IONS Stock Holding History

Alpha DNA Investment Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-50,614
Closed -$1.54M – 136
2021
Q4 		$1.54M Buy
+50,614
New +$1.59M 0.97% 61

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

Alpha DNA Investment Management's IONS Position: Q1 2022 in Review

Alpha DNA Investment Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2022, closing a stake of 50,614 shares — an estimated $1.54M sold.

Alpha DNA Investment Management first reported a position in IONS in Q4 2021 and held it in 1 quarter. The position peaked at $1.54M in Q4 2021. 332 funds tracked by Wall St. Rank hold IONS as of Q1 2022.

  • Alpha DNA Investment Management reported no remaining Ionis Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Alpha DNA Investment Management sold 50,614 Ionis Pharmaceuticals shares in Q1 2022, an estimated $1.54M.
  • Alpha DNA Investment Management first reported a position in Ionis Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Alpha DNA Investment Management's Ionis Pharmaceuticals position peaked at $1.54M in Q4 2021.
  • 332 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2022.

Based on Alpha DNA Investment Management's 13F filing for Q1 2022, filed 13 May 2022.